Skip to main content
SpringerLink
Log in

Prophylactic Hepatitis E Vaccine

  • Chapter
  • First Online:
Hepatitis E Virus

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1417))

Abstract

The hepatitis E has been increasingly recognized as an underestimated global disease burden in recent years. Subpopulations with more serious infection associated damage or death include pregnant women, patients with basic liver diseases, and elderly persons. Vaccine would be the most effective means for prevention of HEV infection. The lack of an efficient cell culture system for HEV makes the development of classic inactive or attenuated vaccine infeasible. Hence, the recombinant vaccine approaches are explored deeply. The neutralizing sites are located almost exclusively in the capsid protein, pORF2, of the virion. Based on pORF2, many vaccine candidates showed potential of protecting primate animals, two of them were tested in human and evidenced to be well-tolerated in adults and highly efficacious in preventing hepatitis E. The world’s first hepatitis E vaccine, Hecolin® (HEV 239 vaccine), was licensed in China and launched in 2012.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

HEV:

Hepatitis E Virus

mAb:

Monoclonal antibody

HE:

Hepatitis E

NHP:

Non-human primate

VLP:

Virus-like particle

ORF:

Open reading frame

References

  1. Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al (2012) Hepatitis E. Lancet 379(9835):2477–2488

    Article  PubMed  Google Scholar 

  2. Teshale EH, Howard CM, Grytdal SP, Handzel TR, Barry V, Kamili S et al (2010) Hepatitis E epidemic, Uganda. Emerg Infect Dis 16(1):126–129

    Article  PubMed  Google Scholar 

  3. Boccia D, Guthmann JP, Klovstad H, Hamid N, Tatay M, Ciglenecki I et al (2006) High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur. Clin Infect Dis 42(12):1679–1684

    Article  PubMed  Google Scholar 

  4. Wu T, Li SW, Zhang J, Ng MH, Xia NS, Zhao Q (2012) Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother 8(6):823–827

    Article  CAS  PubMed  Google Scholar 

  5. Zhang J, Liu CB, Li RC, Li YM, Zheng YJ, Li YP et al (2009) Randomized-controlled phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine 27(12):1869–1874

    Article  CAS  PubMed  Google Scholar 

  6. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ et al (2010) Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376(9744):895–902

    Article  CAS  PubMed  Google Scholar 

  7. Bryan JP, Tsarev SA, Iqbal M, Ticehurst J, Emerson S, Ahmed A et al (1994) Epidemic hepatitis-E in Pakistan - patterns of serologic response and evidence that antibody to hepatitis-E virus protects against disease. J Infect Dis 170(3):517–521

    Article  CAS  PubMed  Google Scholar 

  8. Krawczynski K, Meng XJ, Rybczynska J (2011) Pathogenetic elements of hepatitis E and animal models of HEV infection. Virus Res 161(1):78–83

    Article  CAS  PubMed  Google Scholar 

  9. Arankalle VA, Chadha MS, Chobe LP (1999) Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus. J Hepatol 30(2):199–204

    Article  CAS  PubMed  Google Scholar 

  10. Arankalle VA, Chadha MS, Chobe LP, Nair R, Banerjee K (1995) Cross-challenge studies in rhesus monkeys employing different Indian isolates of hepatitis E virus. J Med Virol 46(4):358–363

    Article  CAS  PubMed  Google Scholar 

  11. Arankalle VA, Favorov MO, Chadha MS, Phule DM, Banerjee K (1993) Rhesus monkeys infected with hepatitis E virus (HEV) from the former USSR are immune to subsequent challenge with an Indian strain of HEV. Acta Virol 37(6):515–518

    CAS  PubMed  Google Scholar 

  12. Schofield DJ, Glamann J, Emerson SU, Purcell RH (2000) Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 74(12):5548–5555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL et al (1994) Successful passive and active immunization of cynomolgus monkeys against hepatitis-E. Proc Natl Acad Sci U S A 91(21):10198–10202

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhang J, Gu Y, Ge SX, Li SW, He ZQ, Huang GY et al (2005) Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein. Vaccine 23(22):2881–2892

    Article  CAS  PubMed  Google Scholar 

  15. Engle RE, Yu C, Emerson SU, Meng XJ, Purcell RH (2002) Hepatitis E virus (HEV) capsid antigens derived from viruses of human and swine origin are equally efficient for detecting anti-HEV by enzyme immunoassay. J Clin Microbiol 40(12):4576–4580

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zhang J, Ge SX, Huang GY, Li SW, He ZQ, Wang YB et al (2003) Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. J Med Virol 71(4):518–526

    Article  CAS  PubMed  Google Scholar 

  17. Emerson SU, Clemente-Casares P, Moiduddin N, Arankalle VA, Torian U, Purcell RH (2006) Putative neutralization epitopes and broad cross-genotype neutralization of Hepatitis E virus confirmed by a quantitative cell-culture assay. J Gen Virol 87(Pt 3):697–704

    Article  CAS  PubMed  Google Scholar 

  18. Meng JH, Pillot J, Dai X, Fields HA, Khudyakov YE (1998) Neutralization of different geographic strains of the hepatitis E virus with anti-hepatitis E virus-positive serum samples obtained from different sources. Virology 249(2):316–324

    Article  CAS  PubMed  Google Scholar 

  19. Huang WJ, Zhang HY, Harrison TJ, Lang SH, Huang GY, Wang YC (2008) Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques. J Med Virol 80(5):824–832

    Article  CAS  PubMed  Google Scholar 

  20. Li SW, Zhang J, Li YA, Ou SH, Huang GY, Huang GY et al (2005) A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 23(22):2893–2901

    Article  CAS  PubMed  Google Scholar 

  21. Purcell RH, Nguyen H, Shapiro M, Engle RE, Govindarajan S, Blackwelder WC et al (2003) Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine 21(19-20):2607–2615

    Article  CAS  PubMed  Google Scholar 

  22. Sanford BJ, Dryman BA, Huang YW, Feagins AR, LeRoith T, Meng XJ (2011) Prior infection of pigs with a genotype 3 swine hepatitis E virus (HEV) protects against subsequent challenges with homologous and heterologous genotypes 3 and 4 human HEV. Virus Res 159(1):17–22

    Article  CAS  PubMed  Google Scholar 

  23. Tang XH, Yang CY, Gu Y, Song CL, Zhang X, Wang YB et al (2011) Structural basis for the neutralization and genotype specificity of hepatitis E virus. Proc Natl Acad Sci U S A 108(25):10266–10271

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Li SW, Tang XH, Seetharaman J, Yang CY, Gu Y, Zhang J et al (2009) Dimerization of hepatitis E virus capsid protein E2s domain is essential for virus-host interaction. PLoS Pathog 5(8):e1000537

    Article  PubMed  PubMed Central  Google Scholar 

  25. Zhang J, Li SW, Wu T, Zhao QJ, Ng MH, Xia NS (2012) Hepatitis E virus: neutralizing sites, diagnosis, and protective immunity. Rev Med Virol 22(5):339–349

    Article  CAS  PubMed  Google Scholar 

  26. Nan Y, Yu Y, Ma Z, Khattar SK, Fredericksen B, Zhang YJ (2014) Hepatitis E virus inhibits type I interferon induction by ORF1 products. J Virol 88(20):11924–11932

    Article  PubMed  PubMed Central  Google Scholar 

  27. Yamada K, Takahashi M, Hoshino Y, Takahashi H, Ichiyama K, Nagashima S et al (2009) ORF3 protein of hepatitis E virus is essential for virion release from infected cells. J Gen Virol 90:1880–1891

    Article  CAS  PubMed  Google Scholar 

  28. Li SW, Zhao QJ, Wu T, Chen S, Zhang J, Xia NS (2015) The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccin Immunother 11(4):908–914

    Article  PubMed  PubMed Central  Google Scholar 

  29. Shrestha MP, Scott RM, Joshi DM, Mammen MP, Thapa GB, Thapa N et al (2007) Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 356(9):895–903

    Article  CAS  PubMed  Google Scholar 

  30. Zhou YH, Purcell RH, Emerson SU (2005) A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine 23(24):3157–3165

    Article  CAS  PubMed  Google Scholar 

  31. Khudyakov YE, Lopareva EN, Jue DL, Crews TK, Thyagarajan SP, Fields HA (1999) Antigenic domains of the open reading frame 2-encoded protein of hepatitis E virus. J Clin Microbiol 37(9):2863–2871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhang HM, Dai X, Shan XN, Meng JH (2009) Characterization of antigenic epitopes of the ORF2 protein from hepatitis E virus genotype 4. Virus Res 142(1-2):140–143

    Article  CAS  PubMed  Google Scholar 

  33. Khudyakov YE, Favorov MO, Jue DL, Hine TK, Fields HA (1994) Immunodominant antigenic regions in a structural protein of the hepatitis-E virus. Virology 198(1):390–393

    Article  CAS  Google Scholar 

  34. Li F, Torresi J, Locarnini SA, Zhuang H, Zhu WF, Guo XX et al (1997) Amino-terminal epitopes are exposed when full-length open reading frame 2 of hepatitis E virus is expressed in Escherichia coli, but carboxy-terminal epitopes are masked. J Med Virol 52(3):289–300

    Article  CAS  PubMed  Google Scholar 

  35. Zhang JZ, Ng MH, Xia NS, Lau SH, Che XY, Chau TN et al (2001) Conformational antigenic determinants generated by interactions between a bacterially expressed recombinant peptide of the hepatitis C virus structural protein. J Med Virol 64(2):125–132

    Article  CAS  PubMed  Google Scholar 

  36. Meng J, Dai X, Chang JC, Lopareva E, Pillot J, Fields HA et al (2001) Identification and characterization of the neutralization epitope(s) of the hepatitis E virus. Virology 288(2):203–211

    Article  CAS  PubMed  Google Scholar 

  37. Zheng Q, Jiang J, He M, Zheng Z, Yu H, Li T et al (2019) Viral neutralization by antibody-imposed physical disruption. Proc Natl Acad Sci U S A 116(52):26933–26940

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gu Y, Tang X, Zhang X, Song C, Zheng M, Wang K et al (2015) Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody. Cell Res 25(5):604–620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Xing L, Wang JC, Li TC, Yasutomi Y, Lara J, Khudyakov Y et al (2011) Spatial configuration of hepatitis E virus antigenic domain. J Virol 85(2):1117–1124

    Article  CAS  PubMed  Google Scholar 

  40. Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H et al (2009) Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A 106(31):12986–12991

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Wen GP, He L, Tang ZM, Wang SL, Zhang X, Chen YZ et al (2020) Quantitative evaluation of protective antibody response induced by hepatitis E vaccine in humans. Nat Commun 11(1):3971

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Wei M, Zhang X, Yu H, Tang ZM, Wang K, Li Z et al (2014) Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes. Vaccine 32(24):2859–2865

    Article  CAS  PubMed  Google Scholar 

  43. Yang C, Pan H, Wei M, Zhang X, Wang N, Gu Y et al (2013) Hepatitis E virus capsid protein assembles in 4M urea in the presence of salts. Protein Sci 22(3):314–326

    Article  CAS  PubMed  Google Scholar 

  44. Guu TS, Liu Z, Ye Q, Mata DA, Li K, Yin C et al (2009) Structure of the hepatitis E virus-like particle suggests mechanisms for virus assembly and receptor binding. Proc Natl Acad Sci U S A 106(31):12992–12997

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Xing L, Kato K, Li T, Takeda N, Miyamura T, Hammar L et al (1999) Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 265(1):35–45

    Article  CAS  PubMed  Google Scholar 

  46. Xing L, Li TC, Mayazaki N, Simon MN, Wall JS, Moore M et al (2010) Structure of hepatitis E virion-sized particle reveals an RNA-dependent viral assembly pathway. J Biol Chem 285(43):33175–33183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Zhang X, Wei M, Pan H, Lin Z, Wang K, Weng Z et al (2014) Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin®. Vaccine 32(32):4039–4050

    Article  CAS  PubMed  Google Scholar 

  48. Li SW, Zhang J, He ZQ, Gu Y, Liu RS, Lin J et al (2005) Mutational analysis of essential interactions involved in the assembly of hepatitis E virus capsid. J Biol Chem 280(5):3400–3406

    Article  CAS  PubMed  Google Scholar 

  49. Li TC, Takeda N, Miyamura T, Matsuura Y, Wang JC, Engvall H et al (2005) Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol 79(20):12999–13006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Khuroo MS, Khuroo MS (2016) Hepatitis E: an emerging global disease - from discovery towards control and cure. J Viral Hepat 23(2):68–79

    Article  CAS  PubMed  Google Scholar 

  51. Purdy MA, Mccaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW (1993) Preliminary evidence that a Trpe-Hev fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis-E virus (Hev). J Med Virol 41(1):90–94

    Article  CAS  PubMed  Google Scholar 

  52. Robinson RA, Burgess WH, Emerson SU, Leibowitz RS, Sosnovtseva SA, Tsarev S et al (1998) Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expr Purif 12(1):75–84

    Article  CAS  PubMed  Google Scholar 

  53. Tsarev SA, Tsareva TS, Emerson SU, Kapikian AZ, Ticehurst J, London W et al (1993) ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates. J Infect Dis 168(2):369–378

    Article  CAS  PubMed  Google Scholar 

  54. Zhang M, Emerson SU, Nguyen H, Engle RE, Govindarajan S, Gerin JL et al (2001) Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells. Vaccine 20(5-6):853–857

    Article  CAS  PubMed  Google Scholar 

  55. Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL et al (1997) Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 15(17-18):1834–1838

    Article  CAS  PubMed  Google Scholar 

  56. Zhang M, Emerson SU, Nguyen H, Engle R, Govindarajan S, Blackwelder WC et al (2002) Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. Vaccine 20(27-28):3285–3291

    Article  CAS  PubMed  Google Scholar 

  57. Huang WJ, Zhang HY, Harrison TJ, Lan HY, Huang GY, Wang YC (2009) Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4. Arch Virol 154(3):481–488

    Article  CAS  PubMed  Google Scholar 

  58. Li TC, Yamakawa Y, Suzuki K, Tatsumi M, Razak MA, Uchida T et al (1997) Expression and self-assembly of empty virus-like particles of hepatitis E virus. J Virol 71(10):7207–7213

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ge S, Zhang J, Huang G, Pang S, Zhou K, Xia N (2003) The immuno-protect study of a hepatitis E virus ORF2 peptide expressed in E. coli. Acta Microbiol Sin 43(1):35–42

    Google Scholar 

  60. Wu T, Wu XL, Ou SH, Lin CX, Cheng T, Li SW et al (2007) Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity. Mol Immunol 44(12):3261–3266

    Article  CAS  PubMed  Google Scholar 

  61. Park SB (2012) Hepatitis E vaccine debuts. Nature 491(7422):21–22

    Article  CAS  PubMed  Google Scholar 

  62. Safary A (2001) Perspectives of vaccination against hepatitis E. Intervirology 44(2-3):162–166

    Article  CAS  PubMed  Google Scholar 

  63. Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ et al (2015) Long-term efficacy of a hepatitis E vaccine. N Engl J Med 372(10):914–922

    Article  CAS  PubMed  Google Scholar 

  64. Chen S, Zhou Z, Wei FX, Huang SJ, Tan Z, Fang Y et al (2015) Modeling the long-term antibody response of a hepatitis E vaccine. Vaccine 33(33):4124–4129

    Article  CAS  PubMed  Google Scholar 

  65. Wu T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, Zhang J et al (2012) Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 55(6):2038

    Article  PubMed  Google Scholar 

  66. Yu XY, Chen ZP, Wang SY, Pan HR, Wang ZF, Zhang QF et al (2019) Safety and immunogenicity of hepatitis E vaccine in elderly people older than 65years. Vaccine 37(32):4581–4586

    Article  CAS  PubMed  Google Scholar 

  67. Zhang L (2018) Immunogenicity and safety of hepatitis E vaccine in chronic hepatitis b patients: an open-label control study in China. Hepatology 68:1181a

    Google Scholar 

  68. 陈剑惠, 张宏, 翁美榕 (2019) 戊型肝炎疫苗与乙型肝炎疫苗联合接种的安全性. 解放军 预防医学杂志 40: 451–6.

    Google Scholar 

  69. Chen Z, Lin S, Duan J, Luo Y, Wang S, Gan Z et al (2019) Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: a randomized, controlled, open-label, phase IV trial. Clin Microbiol Infect 25(9):1133–1139

    Article  CAS  PubMed  Google Scholar 

  70. Qiao YL, Wu T, Li RC, Hu YM, Wei LH, Li CG et al (2020) Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial. J Natl Cancer Inst 112(2):145–153

    Article  PubMed  Google Scholar 

  71. Zhang Y, Li M, Yang F, Li Y, Zheng Z, Zhang X et al (2015) Comparable quality attributes of hepatitis E vaccine antigen with and without adjuvant adsorption-dissolution treatment. Hum Vaccin Immunother 11(5):1129–1139

    Article  PubMed  PubMed Central  Google Scholar 

  72. Hamid SS, Jafri SM, Khan H, Shah H, Abbas Z, Fields H (1996) Fulminant hepatic failure in pregnant women: acute fatty liver or acute viral hepatitis? J Hepatol 25(1):20–27

    Article  CAS  PubMed  Google Scholar 

  73. Kmush BL, Nelson KE, Labrique AB (2015) Risk factors for hepatitis E virus infection and disease. Expert Rev Anti-Infect Ther 13(1):41–53

    Article  CAS  PubMed  Google Scholar 

  74. Kumar A, Beniwal M, Kar P, Sharma JB, Murthy NS (2004) Hepatitis E in pregnancy. Int J Gynaecol Obstet 85(3):240–244

    Article  CAS  PubMed  Google Scholar 

  75. Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK (2007) Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med 147(1):28–33

    Article  PubMed  Google Scholar 

  76. Labrique AB, Sikder SS, Krain LJ, West KP, Christian P, Rashid M et al (2012) Hepatitis E, a vaccine-preventable cause of maternal deaths. Emerg Infect Dis 18(9):1401–1404

    Article  PubMed  PubMed Central  Google Scholar 

  77. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A et al (2002) Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 36(2):474–478

    Article  PubMed  Google Scholar 

  78. Ramachandran J, Eapen CE, Kang G, Abraham P, Hubert DD, Kurian G et al (2004) Hepatitis E superinfection produces severe decompensation in patients with chronic liver disease. J Gastroenterol Hepatol 19(2):134–138

    Article  PubMed  Google Scholar 

  79. Kumar Acharya S, Kumar Sharma P, Singh R, Kumar Mohanty S, Madan K, Kumar Jha J et al (2007) Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 46(3):387–394

    Article  PubMed  Google Scholar 

  80. Zhu FC, Huang SJ, Wu T, Zhang XF, Wang ZZ, Ai X et al (2014) Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China. PLoS One 9(1):e87154

    Article  PubMed  PubMed Central  Google Scholar 

  81. Feray C, Pawlotsky JM, Roque-Afonso AM, Samuel D, Dhumeaux D (2014) Should we screen blood products for hepatitis E virus RNA? Lancet 383(9913):218

    Article  PubMed  Google Scholar 

  82. Gallian P, Lhomme S, Piquet Y, Saune K, Abravanel F, Assal A et al (2014) Hepatitis E virus infections in blood donors. Emerg Infect Dis 20(11):1914–1917

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B et al (2014) Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet 384(9956):1766–1773

    Article  PubMed  Google Scholar 

  84. Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR (2006) A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. J Virol Methods 131(1):65–71

    Article  CAS  PubMed  Google Scholar 

  85. Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M et al (2015) Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from Catalonia (Spain). Transfusion 55(5):972–979

    Article  CAS  PubMed  Google Scholar 

  86. Wen GP, Tang ZM, Yang F, Zhang K, Ji WF, Cai W et al (2015) A valuable antigen detection method for diagnosis of acute hepatitis E. J Clin Microbiol 53(3):782–788

    Article  PubMed  PubMed Central  Google Scholar 

  87. Abravanel F, Lhomme S, Chapuy-Regaud S, Mansuy JM, Muscari F, Sallusto F et al (2014) Hepatitis E virus reinfections in solid-organ-transplant recipients can evolve into chronic infections. J Infect Dis 209(12):1900–1906

    Article  CAS  PubMed  Google Scholar 

  88. Haagsma EB, van den Berg AP, Porte RJ, Benne CA, Vennema H, Reimerink JH et al (2008) Chronic hepatitis E virus infection in liver transplant recipients. Liver Transpl 14(4):547–553

    Article  PubMed  Google Scholar 

  89. Halac U, Beland K, Lapierre P, Patey N, Ward P, Brassard J et al (2012) Chronic hepatitis E infection in children with liver transplantation. Gut 61(4):597–603

    Article  CAS  PubMed  Google Scholar 

  90. Gerolami R, Moal V, Colson P (2008) Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 358(8):859–860

    Article  CAS  PubMed  Google Scholar 

  91. Haagsma EB, Niesters HG, van den Berg AP, Riezebos-Brilman A, Porte RJ, Vennema H et al (2009) Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 15(10):1225–1228

    Article  PubMed  Google Scholar 

  92. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C et al (2011) Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 140(5):1481–1489

    Article  PubMed  Google Scholar 

  93. Pas SD, de Man RA, Mulders C, Balk AH, van Hal PT, Weimar W et al (2012) Hepatitis E virus infection among solid organ transplant recipients, the Netherlands. Emerg Infect Dis 18(5):869–872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Pischke S, Suneetha PV, Baechlein C, Barg-Hock H, Heim A, Kamar N et al (2010) Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 16(1):74–82

    Article  PubMed  Google Scholar 

  95. Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Kruger DH et al (2012) Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient. J Hepatol 56(2):500–502

    Article  CAS  PubMed  Google Scholar 

  96. Wedemeyer H, Pischke S, Manns MP (2012) Pathogenesis and treatment of hepatitis e virus infection. Gastroenterology 142(6):1388–1397

    Article  CAS  PubMed  Google Scholar 

  97. Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, Cunningham R et al (2005) Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 192(7):1166–1172

    Article  CAS  PubMed  Google Scholar 

  98. Torresi J, Johnson D (2011) Hepatitis A and E infection in international travellers. Curr Infect Dis Rep 13(3):248–255

    Article  PubMed  Google Scholar 

  99. WHO (2016) Hepatitis E vaccine: WHO position paper, May 2015–recommendations. Vaccine 34(3):304–305

    Article  Google Scholar 

  100. Teshale E, Ward JW (2015) Making hepatitis E a vaccine-preventable disease. N Engl J Med 372(10):899–901

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China

    Jun Zhang, Zizheng Zheng & Ningshao Xia

Authors
  1. Jun Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zizheng Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ningshao Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jun Zhang .

Editor information

Editors and Affiliations

  1. Institute of Medical Biology, Chinese Academy of Medical Science & Peking Union Medical College, Kunming, China

    Youchun Wang

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhang, J., Zheng, Z., Xia, N. (2023). Prophylactic Hepatitis E Vaccine. In: Wang, Y. (eds) Hepatitis E Virus. Advances in Experimental Medicine and Biology, vol 1417. Springer, Singapore. https://doi.org/10.1007/978-981-99-1304-6_16

Download citation

Publish with us

Policies and ethics

Search

Navigation